CN114269339A - 一种萘脲类化合物的应用 - Google Patents

一种萘脲类化合物的应用 Download PDF

Info

Publication number
CN114269339A
CN114269339A CN201980099600.9A CN201980099600A CN114269339A CN 114269339 A CN114269339 A CN 114269339A CN 201980099600 A CN201980099600 A CN 201980099600A CN 114269339 A CN114269339 A CN 114269339A
Authority
CN
China
Prior art keywords
substance
eye
halogen
medicament
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980099600.9A
Other languages
English (en)
Inventor
张飞
王森
张艳宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Rui Ming New Drug R & D Co ltd
Original Assignee
Suzhou Rui Ming New Drug R & D Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Rui Ming New Drug R & D Co ltd filed Critical Suzhou Rui Ming New Drug R & D Co ltd
Priority to CN202410576216.6A priority Critical patent/CN118477072A/zh
Publication of CN114269339A publication Critical patent/CN114269339A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种物质A在制备药物中的应用。所述的物质A为如式I所示的萘脲类化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型或其互变异构体，所述的药物为用于治疗眼角膜新生血管病的药物。本发明的萘脲类化合物可以通过滴眼的给药方式治疗眼角膜新生血管病。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201980099600.9A 2019-12-16 2019-12-16 一种萘脲类化合物的应用 Pending CN114269339A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410576216.6A CN118477072A (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/125567 WO2021119902A1 (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410576216.6A Division CN118477072A (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用

Publications (1)

Publication Number Publication Date
CN114269339A true CN114269339A (zh) 2022-04-01

Family

ID=76476949

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980099600.9A Pending CN114269339A (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用
CN202410576216.6A Pending CN118477072A (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410576216.6A Pending CN118477072A (zh) 2019-12-16 2019-12-16 一种萘脲类化合物的应用

Country Status (6)

Country Link
US (1) US20230062969A1 (zh)
EP (1) EP4079303A4 (zh)
JP (1) JP7426754B2 (zh)
CN (2) CN114269339A (zh)
AU (1) AU2019478778B2 (zh)
WO (1) WO2021119902A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024124411A1 (zh) * 2022-12-13 2024-06-20 苏州锐明新药研发有限公司 萘脲类化合物在制备治疗翼状胬肉的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524421A (zh) * 2013-09-29 2014-01-22 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201127A2 (en) * 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524421A (zh) * 2013-09-29 2014-01-22 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
管丽丽等: "酪氨酸蛋白激酶抑制兔角膜新生血管的实验研究", 《激光杂志》, vol. 31, no. 3, pages 80 - 81 *

Also Published As

Publication number Publication date
JP2023506060A (ja) 2023-02-14
JP7426754B2 (ja) 2024-02-02
US20230062969A1 (en) 2023-03-02
CN118477072A (zh) 2024-08-13
EP4079303A4 (en) 2023-08-23
AU2019478778A1 (en) 2022-07-07
AU2019478778B2 (en) 2024-05-02
EP4079303A1 (en) 2022-10-26
WO2021119902A1 (zh) 2021-06-24

Similar Documents

Publication Publication Date Title
Morton et al. Refining procedures for the administration of substances
JP7079243B2 (ja) 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
ES2266512T3 (es) Composiciones para inhibir angiogenesis.
Mouney et al. Effects of acepromazine maleate or morphine on tear production before, during, and after sevoflurane anesthesia in dogs
JP7248836B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
WO2024041330A1 (zh) Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN114269339A (zh) 一种萘脲类化合物的应用
CN112972467A (zh) 一种萘脲类化合物的应用
CN115487183B (zh) 萘脲类化合物在制备治疗翼状胬肉的药物中的应用
RU2528912C1 (ru) Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола, содержащие композицию витаминов группы в
US10322129B2 (en) Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same
Dalla et al. Feline corneal sequestration: a review of medical treatment in 37 cases
KR20160100302A (ko) 라퀴니모드를 사용하는 녹내장의 치료
US20200093842A1 (en) Novel treatments for free-living amoebic infections
RU2703302C1 (ru) Применение раствора оксиэтиламмония метилфеноксиацетата
US20230181703A1 (en) Composition comprising pepstatin and alginic acid or a salt thereof, and use thereof
RU2704354C1 (ru) Способ предупреждения развития помутнения роговицы при ее механических травмах
JP7197112B2 (ja) 水泡性角膜症治療用医薬組成物
US20240285573A1 (en) Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
WO2022242769A1 (zh) 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用
RU2700589C1 (ru) Способ ускорения заживления роговицы при ее механических травмах
CN117731676A (zh) 沙瑞环素在制备抗血小板聚集药物中的应用
WO2024124411A1 (zh) 萘脲类化合物在制备治疗翼状胬肉的药物中的应用
KR20230007245A (ko) 이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도
CN117243949A (zh) 蟛蜞菊内酯在制备治疗脑缺血再灌注损伤药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination